药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Carbetocin
Ebola Zaire vaccine (live, attenuated)
The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Modified vaccinia ankara
The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Teriflunomide.
Carbetocin
Varicella Zoster Vaccine (Recombinant)
The therapeutic efficacy of Varicella Zoster Vaccine (Recombinant) can be decreased when used in combination with Teriflunomide.
Carbetocin
Yersinia pestis 195/p antigen (formaldehyde inactivated)
The therapeutic efficacy of Yersinia pestis 195/p antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Pertussis vaccine
The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Teriflunomide.
Carbetocin
Smallpox (Vaccinia) Vaccine, Live
The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen
The therapeutic efficacy of Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)
The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Typhoid vaccine
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Teriflunomide.
Carbetocin
Tecemotide
The therapeutic efficacy of Tecemotide can be decreased when used in combination with Teriflunomide.
Carbetocin
Hepatitis B Vaccine (Recombinant)
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Teriflunomide.
Carbetocin
Human rabies virus immune globulin
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Teriflunomide.
Carbetocin
Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)
The therapeutic efficacy of Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) can be decreased when used in combination with Teriflunomide.